AU2023215171A1 - Crystalline salt and solvate forms of murizatoclax (amg 397) - Google Patents

Crystalline salt and solvate forms of murizatoclax (amg 397) Download PDF

Info

Publication number
AU2023215171A1
AU2023215171A1 AU2023215171A AU2023215171A AU2023215171A1 AU 2023215171 A1 AU2023215171 A1 AU 2023215171A1 AU 2023215171 A AU2023215171 A AU 2023215171A AU 2023215171 A AU2023215171 A AU 2023215171A AU 2023215171 A1 AU2023215171 A1 AU 2023215171A1
Authority
AU
Australia
Prior art keywords
crystalline form
xrpd pattern
radiation
crystalline
amg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023215171A
Other languages
English (en)
Inventor
Michal ACHMATOWICZ
Mary Chaves
Robert P. FARRELL
James E. HUCKLE
Ron C. KELLY
Van LUU
Stephan Parent
Darren L REID
Jing TENG
Tian Wu
Lingyun Xiao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of AU2023215171A1 publication Critical patent/AU2023215171A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU2023215171A 2022-02-04 2023-02-03 Crystalline salt and solvate forms of murizatoclax (amg 397) Pending AU2023215171A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263306781P 2022-02-04 2022-02-04
US63/306,781 2022-02-04
PCT/US2023/012252 WO2023150250A1 (en) 2022-02-04 2023-02-03 Crystalline salt and solvate forms of murizatoclax (amg 397)

Publications (1)

Publication Number Publication Date
AU2023215171A1 true AU2023215171A1 (en) 2024-07-04

Family

ID=86054183

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023215171A Pending AU2023215171A1 (en) 2022-02-04 2023-02-03 Crystalline salt and solvate forms of murizatoclax (amg 397)

Country Status (7)

Country Link
US (1) US20250122224A1 (https=)
EP (1) EP4472985A1 (https=)
JP (1) JP2025505142A (https=)
AU (1) AU2023215171A1 (https=)
CA (1) CA3248348A1 (https=)
MX (1) MX2024009650A (https=)
WO (1) WO2023150250A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4519271A1 (en) 2022-05-04 2025-03-12 Gilead Sciences, Inc. Salts and polymorphs of certain mcl-1 inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8576985B2 (en) 2009-09-01 2013-11-05 Aptuit (West Lafayette) Llc Methods for indexing solid forms of compounds
JP6453507B2 (ja) * 2017-03-30 2019-01-16 アムジエン・インコーポレーテツド Ｍｃｌ−１タンパク質を阻害する化合物
JP2021161114A (ja) * 2020-03-31 2021-10-11 アムジエン・インコーポレーテツド Ｍｃｌ−１化合物のメチル化

Also Published As

Publication number Publication date
JP2025505142A (ja) 2025-02-21
US20250122224A1 (en) 2025-04-17
EP4472985A1 (en) 2024-12-11
CA3248348A1 (en) 2023-08-10
MX2024009650A (es) 2024-08-14
WO2023150250A1 (en) 2023-08-10

Similar Documents

Publication Publication Date Title
EP2081921B1 (en) Short-acting benzodiazepine salts and their polymorphic forms
EP3205653B1 (en) Crystal form of bisulfate of jak inhibitor and preparation method therefor
JP2010535176A (ja) ジヒドロプテリジノン誘導体の結晶形
CN113840604A (zh) Jak2抑制剂的结晶形式
US20250122224A1 (en) Crystalline Salt and Solvate Forms Of Murizatoclax (AMG 397)
KR102221856B1 (ko) 신규한 피마살탄 결정형의 다형체
AU2017378785A1 (en) Crystalline salts and polymorphs of a P2X3 antagonist
CA3239187A1 (en) Mono-p-toluenesulfonate of axl kinase inhibitor and crystal form thereof
US20250115622A1 (en) Crystalline Forms Of An MCL-1 Inhibitor
US12351588B2 (en) Salt forms and solvates of Mcl-1 antagonists
US20240140966A1 (en) Amorphous and crystalline forms of mcl-1 antagonists
US20250002453A1 (en) Pharmaceutically acceptable salt of eliglustat and crystal form thereof
EP4382528A1 (en) Crystal form of ripk1 inhibitor, acid salt thereof, and crystal form of acid salt thereof
EP4177257A1 (en) Succinate of octahydrothienoquinoline compound, and crystals thereof
JP2022527931A (ja) フロピリミジン化合物の酸付加塩の結晶形
AU2022234309B2 (en) Crystalline salt of a multi-tyrosine kinase inhibitor, method of preparation, and use thereof
JP2022527461A (ja) Ｅｒｋ阻害剤としての５，６－ジヒドロ－４ｈ－チエノ［２，３－ｃ］ピロール－４－オン化合物の塩
KR20210017070A (ko) 신규한 티카그렐러의 결정형, 이의 제조방법 또는 용도
KR102215625B1 (ko) 신규한 에독사반 헤미나프탈렌다이설퍼닉산 염 및 그의 다형체
HK40088128A (en) Salt of compound and pharmaceutical composition containing salt
WO2019011337A1 (zh) Qaw-039的晶型及其制备方法和用途